Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

1Q Revenues: $11.8 billion (-5%)

1Q Earnings: $2.8 billion (-18%)

Comments: Pharmaceutical revenues in the quarter were $10.9 billion (-6%). Lipitor revenues were $3.1 billion (-7%), Celebrex revenues were $611 million (+2%), Lyrica revenues were $582 million (+47%). Revenues from new products, Sutent and Chantix, were $190 million (+86%) and $277 million (+71%), respectively, despite added warnings to the label of Chantix in January 2008. Revenue decline in the quarter was primarily due to the U.S. losses of exclusivity of Norvasc (March 2007) and Zyrtec (January 2008), while earnings were dented further by increased in-process R&D expenses associated with acquisitions of CovX and Coley Pharmaceutical Group. R&D expenses were $1.8 billion in the quarter (+8%).  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters